Simplex Trading
CADL icon

Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Simplex Trading’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.5K Sell
8,500
-31,900
-79% -$241K ﹤0.01% 5717
2026
Q1 		$198K Sell
40,400
-18,300
-31% -$99.6K ﹤0.01% 4310
2025
Q4 		$332K Sell
58,700
-26,100
-31% -$140K ﹤0.01% 3712
2025
Q3 		$432K Buy
84,800
+8,400
+11% +$48.5K ﹤0.01% 4003
2025
Q2 		$386K Buy
76,400
+29,600
+63% +$152K ﹤0.01% 3786
2025
Q1 		$264K Sell
46,800
-14,000
-23% -$114K ﹤0.01% 4045
2024
Q4 		$527K Buy
60,800
+59,000
+3,278% +$349K ﹤0.01% 3484
2024
Q3 		$12K Buy
1,800
+1,600
+800% +$9.94K ﹤0.01% 7049
2024
Q2 		$1K Buy
+200
New +$1.5K ﹤0.01% 8427

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Simplex Trading's CADL Position: Q2 2026 in Review

Simplex Trading reduced its Candel Therapeutics (CADL) stake by 87% in Q2 2026, selling an estimated $86.6K and leaving 1,749 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #7197.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 6 quarters since. The position peaked at $158K in Q3 2024. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Simplex Trading held 1,749 shares of Candel Therapeutics worth $18K as of Q2 2026.
  • Simplex Trading sold 11,467 Candel Therapeutics shares in Q2 2026, an estimated $86.6K.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7197 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.